INTRODUCTION {#s1}
============

In 2012, an estimated 1,824,700 new lung cancer (LC) cases occurred worldwide, accounting for approximately 13% of overall cancer diagnosis \[[@R1]\]. LC was the most common malignancy and the first leading cause of cancer-related death among males in 2012; in addition, it was the second cancer-related death among females \[[@R1]\]. Thus, exploration of potential heredity factors that might affect the risk of LC, especially non-small-cell LC (NSCLC), which was the most common subtype of cases, attracted our interest. We focused on the costimulatory molecules of immunoglobulin superfamily which regulate T-cell activation and proliferation.

Cytotoxic T-lymphocyte antigen-4 (CTLA-4), a member of the immunoglobulin superfamily, is also known as CD152. In generally, CTLA-4 is expressed on activated T cells and negatively regulate the proliferation and the activation of T cells \[[@R2]--[@R4]\]. CTLA-4 competes with CD28 and binds to B7.1 and B7.2 which are costimulatory molecules expressed on antigen-presenting cells. In addition, the affinity between CTLA-4 and B7 molecules is higher than that of CD28 with B7 molecules \[[@R5], [@R6]\]. The interaction of CTLA-4--B7 leads to the repression of T cells at the G~1~ phase and the down-regulated expression of interleukin-2 (IL-2) and IL-2 receptor \[[@R7]\]. This interaction can also induce activated T cells to FAS-independent apoptosis, and then further restrain T lymphocytes.

CTLA-4, a immunoregulatory molecule, is encoded by a gene on chromosome 2q33. A number of single-nucleotide polymorphisms (SNPs) in *CTLA-4* gene have been established. Song et al. reported that *CTLA-4* +49A\>G polymorphism was a prognostic predictor for advanced NSCLC \[[@R8]\]. In addition, Antczak et al. found that CTLA-4 expression was significantly correlated with CTLA-4 TT genotype (-318C/T). Recently, several case-control studies focused on the relationship of *CTLA-4* SNPs with the risk of NSCLC \[[@R8]--[@R12]\]. However, due to the limited sample size and the number of study, the association between *CTLA-4* SNPs and NSCLC susceptibility was not well understood. The objective of this case-control study was to extensively explore the relationship of *CTLA-4* rs16840252 C\>T, rs231775 G\>A, rs3087243 G\>A and rs733618 T\>C polymorphisms with susceptibility to NSCLC.

RESULTS {#s2}
=======

Demographic characteristics {#s2_1}
---------------------------

This case-control study comprised 521 NSCLC cases and 1,030 control subjects. The NSCLC patients comprised 287 males and 234 females, while the non-cancer control subjects were 588 males and 442 females. The mean age and SD in the NSCLC patient was 59.76 ± 10.71 years and that was 60.34 ± 9.11 years in controls. Gender and age were well-matched between the groups (*P* = 0.453 and *P* = 0.843, respectively, Table [1](#T1){ref-type="table"}). All 521 confirmed cases of NSCLC were sporadic. The genotyping successful rates were shown in Table [2](#T2){ref-type="table"} and they ranged from 99.81% to 99.94%. The values of MAF in control subjects were very similar to the data for Chinese (Table [2](#T2){ref-type="table"}). The genotype frequencies of *CTLA-4* rs16840252 C\>T, rs231775 G\>A, rs3087243 G\>A and rs733618 T\>C polymorphisms in controls reached Hardy-Weinberg equilibrium (HWE).

###### Distribution of selected demographic variables and risk factors in NSCLC cases and controls

  Variable                   Overall Cases (*n* = 521)   Overall Controls (*n* = 1,030)   *P*^a^
  -------------------------- --------------------------- -------------------------------- --------------
  Age (years)                59.76 ±10.71                60.34 ± 9.11                     0.268
  Age (years)                                                                             0.843
   \< 60                     238 (45.68)                 476 (46.21)                      
   ≥ 60                      283 (54.32)                 554 (53.79)                      
  Sex                                                                                     0.453
   Male                      287 (55.09)                 588 (57.09)                      
   Female                    234 (44.91)                 442 (42.91)                      
  Smoking status                                                                          **\< 0.001**
   Never                     317 (60.84)                 828 (80.39)                      
   Ever                      204 (39.16)                 202 (19.61)                      
  Alcohol use                                                                             **\< 0.001**
   Never                     444 (85.22)                 949 (92.14)                      
   Ever                      77 (14.78)                  81 (7.86)                        
  BMI (kg/m^2^)              23.00 (±3.03)               23.84 (±3.06)                    **\< 0.001**
  BMI (kg/m^2^)                                                                           
   \< 24                     337 (64.68)                 547 (53.11)                      **\< 0.001**
   ≥ 24                      184 (35.32)                 483 (46.89)                      
  Lymph node status                                                                       
   Positive                  200 (38.39)                                                  
   Negative                  314 (60.27)                                                  
   Unknown                   7 (1.34)                                                     
  TMN stage                                                                               
   I + II                    315 (60.46)                                                  
   III + IV                  206 (39.54)                                                  
  Type of NSCLC                                                                           
   Adenocarcinoma            415 (79.65)                                                  
   Squamous cell carcinoma   85 (16.31)                                                   
   Others                    21 (4.03)                                                    

^a^ Two-sided *χ*^2^ test and student *t* test;

Bold values are statistically significant (*P* \< 0.05);

BMI, body mass index.

NSCLC: non-small-cell lung cancer

###### Primary information for *CTLA-4* polymorphisms (rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C and rs231775 G\>A)

  Genotyped SNPs                              *CTLA-4*rs3087243 G\>A   *CTLA-4*rs16840252 C\>T   *CTLA-4*rs733618 T\>C   *CTLA-4*rs231775 G\>A
  ------------------------------------------- ------------------------ ------------------------- ----------------------- -----------------------
  Chromosome                                  2                        2                         2                       2
  Function                                    nearGene-3               nearGene-5                nearGene-5              missense
  Chr Pos (NCBI Build 38)                     203874196                203866796                 203866221               203867991
  MAF^a^ for Chinese in database              0.183                    0.122                     0.390                   0.314
  MAF in our controls (*n* ***=***1,040)      0.182                    0.121                     0.407                   0.300
  *P* value for HWE^b^ test in our controls   0.532                    0.146                     0.314                   0.950
  Genotyping method                           SNPscan                  SNPscan                   SNPscan                 SNPscan
  \% Genotyping value                         99.94%                   99.94%                    99.94%                  99.81%

^a^MAF: minor allele frequency;

^b^HWE: Hardy--Weinberg equilibrium.

Association of *CTLA-4* rs16840252 C\>T, rs231775 G\>A, rs3087243 G\>A and rs733618 T\>C Polymorphisms with NSCLC {#s2_2}
-----------------------------------------------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} demonstrated the detailed frequencies of *CTLA-4* rs16840252 C\>T, rs231775 G\>A, rs3087243 G\>A and rs733618 T\>C genotypes. Results of the single locus analyses were summarized in Table [4](#T4){ref-type="table"}. We found no statistically significant difference in *CTLA-4* genotype distribution among NSCLC patients and non-cancer controls. The similar findings were observed in the logistic regression analyses.

###### The frequencies of *CTLA-4* rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C and rs231775 G\>A polymorphisms in different NSCLC subgroups

  Genotype          NSCLC Cases (*n* = 521)   Adenocarcinoma (*n* = 415)   Non-adenocarcinoma (*n* = 106)   Controls (*n* = 1,030)                      
  ----------------- ------------------------- ---------------------------- -------------------------------- ------------------------ ---- ------- ----- -------
  rs3087243 G\>A                                                                                                                                        
  GG                344                       66.03                        273                              65.78                    71   66.98   686   66.67
  GA                160                       30.71                        131                              31.57                    29   27.36   312   30.32
  AA                17                        3.26                         11                               2.65                     6    5.66    31    3.01
  A allele          194                       18.62                        153                              18.43                    41   19.34   374   18.17
  rs16840252 C\>T                                                                                                                                       
  CC                400                       76.78                        323                              77.83                    77   72.64   791   76.87
  CT                111                       21.31                        86                               20.72                    25   23.58   228   22.16
  TT                10                        1.92                         6                                1.45                     4    3.77    10    0.97
  T allele          131                       12.57                        98                               11.81                    33   15.57   248   12.05
  rs733618 T\>C                                                                                                                                         
  TT                172                       33.01                        138                              33.25                    34   32.08   370   35.96
  TC                267                       51.25                        214                              51.57                    53   50.00   481   46.74
  CC                82                        15.74                        63                               15.18                    19   17.92   178   17.30
  C allele          431                       41.36                        340                              40.96                    91   42.92   837   40.67
  rs231775 G\>A                                                                                                                                         
  GG                254                       48.85                        206                              49.76                    48   45.28   504   49.03
  GA                219                       42.12                        175                              42.27                    44   41.51   431   41.93
  AA                47                        9.04                         33                               7.97                     14   13.21   93    9.05
  A allele          313                       30.10                        241                              29.11                    72   33.96   617   30.01

###### Logistic regression analyses of association between *CTLA-4* polymorphisms and risk of NSCLC

  Genotype           Overall NSCLC cases (*n* = 521) vs. controls (*n* = 1030)   Adenocarcinoma (*n* = 415) vs. controls (n=1030)   Non-adenocarcinoma (*n* = 106) vs. controls (*n* = 1030)                                                                                                                     
  ------------------ ----------------------------------------------------------- -------------------------------------------------- ---------------------------------------------------------- ------- ------------------- ------- ------------------- ------- -------------------- ------- -------------------- -------
  rs3087243 G\>A                                                                                                                                                                                                                                                                                                 
  Additive model     1.02 (0.81--1.29)                                           0.839                                              1.02 (0.81--1.30)                                          0.852   1.06 (0.83--1.35)   0.663   1.07 (0.83--1.37)   0.627   0.90 (0.57--1.41)    0.646   0.79 (0.48--1.29)    0.342
  Homozygote model   1.10 (0.60--2.01)                                           0.769                                              1.05 (0.56--1.97)                                          0.872   0.89 (0.44--1.80)   0.752   0.89 (0.44--1.83)   0.759   1.87 (0.76--4.64)    0.175   1.51 (0.55--4.16)    0.429
  Dominant model     1.03 (0.82--1.29)                                           0.801                                              1.03 (0.81--1.29)                                          0.836   1.04 (0.82--1.32)   0.747   1.05 (0.82--1.34)   0.708   0.99 (0.65--1.51)    0.948   0.86 (0.54--1.37)    0.517
  Recessive model    1.09 (0.60--1.98)                                           0.788                                              1.05 (0.56--1.95)                                          0.890   0.88 (0.44--1.76)   0.711   0.88 (0.43--1.78)   0.714   1.93 (0.79--4.74)    0.151   1.63 (0.60--4.43)    0.343
  rs16840252 C\>T                                                                                                                                                                                                                                                                                                
  Additive model     0.96 (0.75--1.25)                                           0.779                                              0.96 (0.74--1.26)                                          0.777   0.93 (0.70--1.22)   0.584   0.91 (0.68--1.21)   0.525   1.13 (0.70--1.81)    0.619   1.24 (0.73--2.09)    0.426
  Homozygote model   1.98 (0.82--4.80)                                           0.130                                              1.37 (0.55--3.44)                                          0.499   1.47 (0.53--4.08)   0.458   1.12 (0.39--3.18)   0.838   4.12 (1.26--13.44)   0.019   2.46 (0.62--9.80)    0.200
  Dominant model     1.01 (0.78--1.29)                                           0.967                                              0.98 (0.76--1.28)                                          0.896   0.95 (0.72--1.24)   0.694   0.92 (0.70--1.22)   0.563   1.25 (0.80--1.97)    0.329   1.32 (0.806--2.18)   0.279
  Recessive model    1.99 (0.83--4.82)                                           0.126                                              1.38 (0.55--3.46)                                          0.487   1.50 (0.54--4.14)   0.439   1.14 (0.40--3.24)   0.808   4.00 (1.23--12.98)   0.021   2.34 (0.59--9.23)    0.225
  T allele                                                                                                                                                                                                                                                                                                       
  rs733618 T\>C                                                                                                                                                                                                                                                                                                  
  Additive model     1.20 (0.95--1.51)                                           0.133                                              1.21 (0.95--1.55)                                          0.122   1.20 (0.93--1.54)   0.166   1.20 (0.93--1.56)   0.167   1.20 (0.77--1.89)    0.424   1.30 (0.79--2.12)    0.305
  Homozygote model   0.99 (0.72--1.37)                                           0.969                                              1.07 (0.77--1.49)                                          0.687   0.95 (0.67--1.35)   0.779   1.01 (0.71--1.44)   0.959   1.17 (0.65--2.10)    0.612   1.50 (0.78--2.88)    0.228
  Dominant model     1.14 (0.91--1.42)                                           0.251                                              1.17 (0.93--1.48)                                          0.175   1.13 (0.89--1.43)   0.330   1.15 (0.90--1.47)   0.270   1.19 (0.78--1.82)    0.427   1.34 (0.84--2.14)    0.220
  Recessive model    0.89 (0.67--1.19)                                           0.438                                              0.96 (0.71--1.29)                                          0.762   0.86 (0.63--1.17)   0.329   0.91 (0.66--1.25)   0.546   1.04 (0.62--1.76)    0.871   1.28 (0.72--2.29)    0.400
  rs231775 G\>A                                                                                                                                                                                                                                                                                                  
  Additive model     1.01 (0.81--1.26)                                           0.942                                              0.99 (0.78--1.24)                                          0.901   0.99 (0.78--1.26)   0.951   0.98 (0.76--1.25)   0.839   1.08 (0.70--1.65)    0.737   1.04 (0.65--1.67)    0.861
  Homozygote model   1.00 (0.69--1.47)                                           0.989                                              0.93 (0.63--1.39)                                          0.735   0.87 (0.57--1.33)   0.516   0.83 (0.54--1.29)   0.417   1.59 (0.84--3.00)    0.154   1.23 (0.61--2.50)    0.567
  Dominant model     1.01 (0.82--1.24)                                           0.946                                              0.98 (0.78--1.22)                                          0.837   0.97 (0.77--1.22)   0.802   0.95 (0.75--1.20)   0.677   1.16 (0.78--1.74)    0.463   1.08 (0.69--1.67)    0.737
  Recessive model    1.00 (0.69--1.44)                                           0.996                                              0.94 (0.64--1.38)                                          0.753   0.87 (0.58--1.32)   0.513   0.84 (0.55--1.29)   0.435   1.53 (0.84--2.79)    0.166   1.20 (0.62--2.36)    0.588

^a^ Adjusted for age, sex, smoking status, alcohol use and BMI status

In a stratified analysis by cancer type of NSCLC, logistic regression analyses indicated that there was no difference in genotype distribution of *CTLA-4* rs231775 G\>A, rs16840252 C\>T, rs3087243 G\>A and rs733618 T\>C polymorphisms among different NSCLC types and controls (Table [4](#T4){ref-type="table"}).

Association of *CTLA-4* rs16840252 C\>T, rs231775 G\>A, rs3087243 G\>A and rs733618 T\>C Polymorphisms with NSCLC in a stratification analysis {#s2_3}
----------------------------------------------------------------------------------------------------------------------------------------------

Tables [5](#T5){ref-type="table"}--[7](#T7){ref-type="table"} summarized the genotype frequencies of *CTLA-4* rs3087243 G\>A, rs16840252 C\>T and rs231775 G\>A polymorphisms in the stratified analyses by gender, age, BMI, drinking and smoking status. We found no difference in genotype distribution of *CTLA-4* rs16840252C\>T, rs231775 G\>A and rs3087243 G\>A polymorphisms among NSCLC cases and the control subjects in any subgroup.

###### Stratified analyses between CTLA-4 rs3087243 G\>A polymorphism and NSCLC risk by sex, age, BMI, smoking status and alcohol consumption

  Variable              *CTLA-4* rs3087243 G\>A (case/control)^a^   Adjusted OR^b^ (95% CI); P                                                                                                           
  --------------------- ------------------------------------------- ---------------------------- ------- ------------------------------- ------------------------------- ------------------------------- -------------------------------
  Sex                                                                                                                                                                                                    
  Male                  184/387                                     94/178                       9/22    1.16 (0.84--1.61); *P*: 0.381   0.76 (0.33--1.75); *P*: 0.513   1.11 (0.81--1.52); *P*: 0.531   0.72 (0.31--1.66); *P*: 0.442
  Female                160/299                                     66/134                       8/9     0.89 (0.62--1.28); *P*: 0.541   1.66 (0.62--4.46); *P*: 0.312   0.94 (0.67--1.33); *P*: 0.734   1.72 (0.65--4.59); *P*: 0.277
  Age                                                                                                                                                                                                    
  \< 60                 162/320                                     72/142                       4/13    1.09 (0.76--1.55); *P*: 0.653   0.67 (0.21--2.20); *P*: 0.514   1.05 (0.74--1.49); *P*: 0.785   0.66 (0.20--2.13); *P*: 0.483
  ≥ 60                  182/366                                     88/170                       13/18   1.00 (0.72--1.39); *P*: 0.987   1.33 (0.62--2.86); *P*: 0.459   1.04 (0.76--1.42); *P*: 0.825   1.33 (0.63--2.84); *P*: 0.456
  Smoking status                                                                                                                                                                                         
  Never                 207/556                                     100/249                      10/22   1.06 (0.79--1.41); *P*: 0.708   1.21 (0.55--2.65); *P*: 0.632   1.07 (0.81--1.42); *P*: 0.647   1.19 (0.55--2.58); *P*: 0.665
  Ever                  137/130                                     60/63                        7/9     0.90 (0.58--1.39); *P*: 0.630   0.77 (0.27--2.14); *P*: 0.610   0.88 (0.58--1.34); *P*: 0.556   0.79 (0.29--2.19); *P*: 0.653
  Alcohol consumption                                                                                                                                                                                    
  Never                 292/636                                     138/285                      14/27   1.01 (0.78--1.31); *P*: 0.927   1.04 (0.52--2.06); *P*: 0.916   1.01 (0.79--1.30); *P*: 0.918   1.03 (0.52--2.04); *P*: 0.926
  Ever                  52/50                                       22/27                        3/4     0.96 (0.46--1.99); *P*: 0.911   0.76 (0.15--3.91); *P*: 0.747   0.93 (0.46--1.87); *P*: 0.842   0.77 (0.15--3.90); *P*: 0.756
  BMI (kg/m^2^)                                                                                                                                                                                          
   \< 24                223/350                                     104/178                      10/18   0.91 (0.67--1.24); *P*: 0.546   0.95 (0.42--2.18); *P*: 0.911   0.91 (0.68--1.23); *P*: 0.546   0.98 (0.43--2.23); *P*: 0.967
   ≥ 24                 121/336                                     56/134                       7/13    1.21 (0.82--1.78); *P*: 0.343   1.13 (0.42--3.06); *P*: 0.806   1.20 (0.83--1.74); *P*: 0.342   1.07 (0.40--2.86); *P*: 0.985

^a^ The genotyping was successful in 521 (100.00%) NSCLC cases, and 1029 (99.90%) controls for *CTLA-4* rs3087243 G\>A; ^b^ Adjusted for age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

###### Stratified analyses between *CTLA-4* rs16840252 C\>T polymorphism and NSCLC risk by sex, age, BMI, smoking status and alcohol consumption

  Variable              *CTLA-4* rs16840252 C\>T (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                                           
  --------------------- -------------------------------------------- ------------------------------ ------ ------------------------------- -------------------------------- ------------------------------- --------------------------------
  Sex                                                                                                                                                                                                       
  Male                  214/462                                      65/121                         8/4    1.23 (0.85--1.78); *P*: 0.269   3.22 (0.90--11.54); *P*: 0.073   1.31 (0.92--1.87); *P*: 0.136   3.08 (0.86--10.99); *P*: 0.084
  Female                186/329                                      46/107                         2/6    0.70 (0.47--1.04); *P*: 0.074   0.39 (0.07--2.04); *P*: 0.262    0.68 (0.46--1.00); *P*: 0.052   0.43 (0.08--2.24); *P*: 0.315
  Age                                                                                                                                                                                                       
  \< 60                 177/367                                      56/102                         5/6    1.08 (0.73--1.60); *P*: 0.701   1.27 (0.37--4.37); *P*: 0.702    1.09 (0.75--1.60); *P*: 0.652   1.25 (0.37--4.28); *P*: 0.722
  ≥ 60                  223/424                                      55/126                         5/4    0.84 (0.58--1.22); *P*: 0.366   1.49 (0.38--5.92); *P*: 0.570    0.87 (0.61--1.25); *P*: 0.448   1.55 (0.39--6.13); *P*: 0.534
  Smoking status                                                                                                                                                                                            
  Never                 245/631                                      70/188                         2/8    0.94 (0.68--1.29); *P*: 0.704   0.46 (0.10--2.22); *P*: 0.333    0.91 (0.67--1.25); *P*: 0.579   0.47 (0.10--2.25); *P*: 0.340
  Ever                  155/160                                      41/40                          8/2    1.04 (0.64--1.71); *P*: 0.874   4.10 (0.84--19.97); *P*: 0.081   1.18 (0.74--1.90); *P*: 0.485   4.07 (0.84--19.72); *P*: 0.082
  Alcohol consumption                                                                                                                                                                                       
  Never                 343/731                                      91/210                         10/7   0.96 (0.72--1.27); *P*: 0.759   2.04 (0.74--5.62); *P*: 0.167    1.00 (0.76--1.32); *P*: 0.996   2.06 (0.75--5.66); *P*: 0.162
  Ever                  57/60                                        20/18                          0/3    1.05 (0.50--2.23); *P*: 0.890   \-                               0.90 (0.44--1.87); *P*: 0.785   \-
  BMI(kg/m^2^)                                                                                                                                                                                              
   \< 24                256/410                                      74/127                         7/9    0.98 (0.70--1.38); *P*: 0.901   1.02 (0.37--2.84); *P*: 0.974    0.98 (0.71--1.36); *P*: 0.906   1.02 (0.37--2.84); *P*: 0.967
   ≥ 24                 144/381                                      37/101                         3/1    0.94 (0.61--1.45); *P*: 0.773   5.70 (0.53--61.80); *P*: 0.152   0.99 (0.65--1.53); *P*: 0.977   5.77 (0.53--62.46); *P*: 0.149

^a^The genotyping was successful in 521 (100.00%) NSCLC cases, and 1029 (99.90%) controls for *CTLA-4* rs16840252 C\>T; ^b^Adjusted for age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

###### Stratified analyses between *CTLA-4* rs231775 G\>A polymorphism and NSCLC risk by sex, age, smoking status and alcohol consumption

  Variable              *CTLA-4* rs231775 G\>A (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                                           
  --------------------- ------------------------------------------ ------------------------------ ------- ------------------------------- ------------------------------- ------------------------------- -------------------------------
  Sex                                                                                                                                                                                                     
  Male                  132/292                                    123/241                        31/54   1.16 (0.85--1.60); *P*: 0.355   1.20 (0.71--2.02); *P*: 0.500   1.18 (0.87--1.60); *P*: 0.286   1.12 (0.68--1.85); *P*: 0.655
  Female                122/212                                    96/190                         16/39   0.81 (0.58--1.14); *P*: 0.233   0.64 (0.34--1.20); *P*: 0.164   0.78 (0.56--1.08); *P*: 0.129   0.70 (0.38--1.29); *P*: 0.254
  Age                                                                                                                                                                                                     
  \< 60                 114/237                                    103/195                        21/43   1.13 (0.80--1.59); *P*: 0.485   1.01 (0.56--1.82); *P*: 0.980   1.11 (0.80--1.53); *P*: 0.550   0.95 (0.54--1.68); *P*: 0.863
  ≥ 60                  140/267                                    116/236                        26/50   0.89 (0.65--1.23); *P*: 0.487   0.88 (0.51--1.51); *P*: 0.640   0.90 (0.66--1.21); *P*: 0.469   0.93 (0.55--1.57); *P*: 0.781
  Smoking status                                                                                                                                                                                          
  Never                 155/407                                    137/346                        24/73   0.98 (0.74--1.30); *P*: 0.893   0.82 (0.50--1.37); *P*: 0.454   0.96 (0.73--1.25); *P*: 0.734   0.83 (0.51--1.36); *P*: 0.461
  Ever                  99/97                                      82/85                          23/20   0.96 (0.63--1.45); *P*: 0.838   1.10 (0.57--2.15); *P*: 0.773   0.99 (0.67--1.46); *P*: 0.942   1.13 (0.59--2.13); *P*: 0.717
  Alcohol consumption                                                                                                                                                                                     
  Never                 218/470                                    183/397                        42/80   0.95 (0.74--1.22); *P*: 0.696   1.04 (0.68--1.60); *P*: 0.842   0.97 (0.77--1.23); *P*: 0.791   1.07 (0.71--1.61); *P*: 0.751
  Ever                  36/34                                      36/34                          5/13    1.13 (0.56--2.29); *P*: 0.726   0.38 (0.12--1.20); *P*: 0.099   0.90 (0.47--1.74); *P*: 0.756   0.36 (0.12--1.08); *P*: 0.068
  BMI(kg/m^2^)                                                                                                                                                                                            
   \< 24                162/249                                    148/238                        27/58   0.99 (0.74--1.34); *P*: 0.966   0.69 (0.41--1.16); *P*: 0.160   0.93 (0.70--1.23); *P*: 0.590   0.69 (0.42--1.13); *P*: 0.144
   ≥ 24                 92/255                                     71/193                         20/35   0.94 (0.64--1.36); *P*: 0.732   1.50 (0.81--2.80); *P*: 0.200   1.04 (0.73--1.47); *P*: 0.848   1.56 (0.86--2.85); *P*: 0.146

^a^The genotyping was successful in 520 (99.81%) NSCLC cases, and 1028 (99.81%) controls for *CTLA-4* rs231775 G\>A; ^b^Adjusted for age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

As shown in Table [8](#T8){ref-type="table"}, the stratified analyses suggested *CTLA-4* rs733618 vatiants were correlated with the development of NSCLC in ≥ 60 years subgroup (TC vs. TT: adjusted odds ratio (OR) = 1.45, 95% confidence intervals (CI) = 1.04--2.02, *P* = 0.030) and even drinking subgroup (TC vs. TT: adjusted OR = 2.27, 95% CI = 1.11--4.60, *P* = 0.024 and TC/CC vs. TT: adjusted OR = 2.26, 95% CI = 1.15--4.43, *P* = 0.018).

###### Stratified analyses between *CTLA-4* rs733618 T\>C polymorphism and NSCLC risk by sex, age, smoking status and alcohol consumption

  Variable              *CTLA-4* rs733618 T\>C (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                                            
  --------------------- ------------------------------------------ ------------------------------ -------- ------------------------------- ------------------------------- ------------------------------- -------------------------------
  Sex                                                                                                                                                                                                      
  Male                  94/211                                     149/271                        44/105   1.28 (0.91--1.79); *P*: 0.156   1.06 (0.67--1.67); *P*: 0.810   1.22 (0.88--1.67); *P*: 0.234   0.91 (0.61--1.38); *P*: 0.669
  Female                78/159                                     118/210                        38/73    1.19 (0.83--1.70); *P*: 0.354   1.14 (0.70--1.85); *P*: 0.607   1.17 (0.84--1.65); *P*: 0.359   1.03 (0.67--1.59); *P*: 0.900
  Age                                                                                                                                                                                                      
  \< 60                 81/163                                     114/226                        43/86    1.01 (0.70--1.46); *P*: 0.948   1.05 (0.66--1.69); *P*: 0.836   1.02 (0.72--1.44); *P*: 0.911   1.04 (0.68--1.59); *P*: 0.847
  ≥ 60                  91/207                                     153/255                        39/92    1.45 (1.04--2.02); P: 0.030     1.09 (0.68--1.74); *P*: 0.729   1.35 (0.99--1.86); *P*: 0.061   0.87 (0.57--1.33); *P*: 0.530
  Smoking status                                                                                                                                                                                           
  Never                 106/295                                    165/380                        46/152   1.24 (0.92--1.66); *P*: 0.155   0.91 (0.61--1.37); *P*: 0.654   1.15 (0.87--1.52); *P*: 0.340   0.80 (0.56--1.16); *P*: 0.242
  Ever                  66/75                                      102/101                        36/26    1.19 (0.77--1.83); *P*: 0.440   1.61 (0.88--2.97); *P*: 0.125   1.27 (0.84--1.93); *P*: 0.253   1.46 (0.84--2.53); *P*: 0.183
  Alcohol consumption                                                                                                                                                                                      
  Never                 149/331                                    225/449                        70/168   1.12 (0.87--1.46); *P*: 0.387   0.99 (0.69--1.41); *P*: 0.944   1.08 (0.85--1.39); *P*: 0.520   0.92 (0.67--1.27); *P*: 0.615
  Ever                  23/39                                      42/32                          12/10    2.27 (1.11--4.60); P: 0.024     2.23 (0.81--6.13); *P*: 0.121   2.26 (1.15--4.43); P: 0.018     1.40 (0.56--3.54); *P*: 0.472
  BMI (kg/m^2^)                                                                                                                                                                                            
   \< 24                112/212                                    173/250                        52/84    1.29 (0.9--1.76); *P*: 0.113    1.18 (0.77--1.81); *P*: 0.459   1.26 (0.94--1.69); *P*: 0.131   1.02 (0.69--1.51); *P*: 0.932
   ≥ 24                 60/158                                     94/231                         30/94    1.11 (0.75--1.65); *P*: 0.610   0.95 (0.56--1.60); *P*: 0.847   1.07 (0.73--1.55); *P*: 0.744   0.89 (0.56--1.42); *P*: 0.631

^a^ The genotyping was successful in 521 (100.00%) NSCLC cases, and 1029 (99.90%) controls for *CTLA-4* rs733618 T\>C; ^b^ Adjusted for age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

SNP haplotypes {#s2_4}
--------------

Using SHESIS online haplotype construction software \[( <http://analysis.bio-x.cn/myAnalysis.php>), Bio-X Inc., Shanghai, China\] \[[@R13]\], we constructed four haplotypes (Table [9](#T9){ref-type="table"}). We found there was no difference in haplotype distribution among NSCLC cases and the control subjects (Table [9](#T9){ref-type="table"}).

###### *CTLA4* haplotype frequencies (%) in cases and controls and risk of NSCLC

  Haplotypes   case (*n* = 1042)   control (*n* = 2060)   Crude OR (95% CI)   *P*                         
  ------------ ------------------- ---------------------- ------------------- ------- ------------------- -------
  C G G C      430                 41.35                  836                 40.66   Reference           
  C G G T      285                 27.40                  595                 28.94   0.93 (0.78--1.12)   0.445
  C A A T      189                 18.17                  374                 18.19   0.98 (0.80--1.21)   0.869
  T A G T      123                 11.83                  239                 11.62   1.00 (0.78--1.28)   0.996
  Others       13                  1.25                   12                  0.58    2.11 (0.95--4.66)   0.060

With the order of *CTLA4* rs16840252 C\>T, rs231775 G\>A, rs3087243 G\>A and rs733618 T\>C in gene position.

The power of the present study (α= 0.05) {#s2_5}
----------------------------------------

For *CTLA-4* rs733618 T\>C, the power value was 0.629 in additive model among ≥ 60 years subgroup, and 0.651 in additive model and 0.692 in dominant model among even drinking subgroup.

DISCUSSION {#s3}
==========

In generally, immune escape may be an important mechanism in the development of malignancies. The costimulatory signal related SNPs, common variants among individuals, may play important roles in the development of human cancers. In the present study, we explored the effect of *CTLA-4* tagging SNPs in NSCLC among Eastern Chinese Han population for the first time. We found that *CTLA-4* tagging polymorphisms might be not correlated with the susceptibility of overall NSCLC. The results of haplotype analysis suggested that there was no difference in haplotype distribution among NSCLC cases and the control subjects. However, in the stratified analyses by age, sex, BMI, alcohol use and smoking status, we found that *CTLA-4* rs733618 T\>C polymorphism was associated with the development of NSCLC in ≥ 60 years and even drinking subgroups.

NSCLC is a multifactorial disease which results from the interaction between individual\'s genetic backgrounds and environmental risk factors. Previous studies have demonstrated that *CTLA-4* rs733618 T\>C polymorphism decreases a transcription factor binding site for nuclear factor 1 and weaken CTLA-4 expression on cell surface \[[@R14], [@R15]\]. Accumulating evidences suggested that *CTLA-4* rs733618 T\>C polymorphism might be associated with the increased risk of systemic lupus erythematosus \[[@R16]--[@R19]\]. However, the relationship of *CTLA-4* rs733618 T\>C polymorphism with the development of cancer was conflicting. With an interest in the correlation of *CTLA-4* rs733618 T\>C polymorphism with cancer susceptibility, a case-control study explored the hypothesis that *CTLA-4* rs733618 T\>C polymorphism was associated with the etiology of NSCLC \[[@R10]\]; however, this study in an Iranian population established null association between *CTLA-4* rs733618 T\>C polymorphism and NSCLC. In the current study, we found that *CTLA-4* rs733618 T\>C polymorphism was associated with the development of NSCLC. In addition, a previous study in China conducted by Li *et al.*, compared with the *CTLA-4* rs733618 T allele, the C allele increased the risk of breast cancer \[[@R20]\]. Our findings might be supported by this study. To the best of our knowledge, the present case-control study was the first study to examine the potential relationship between *CTLA-4* rs733618 T\>C polymorphism and the development of NSCLC in Asians. However, due to the limited sample size, these potential association should be explained with very caution. In the future, more case-control studies with detailed lifestyle and environmental factors data should be conducted to explore these potential association.

We should acknowledge some limitations in this case-control study. Firstly, the NSCLC patients and control subjects were enrolled from local hospitals in Eastern China and might not fully represent the general Chinese Han population. Secondly, the moderate sample size of NSCLC cases might limit the statistical power to obtain a real assessment, especially in the stratified analyses. Further well-designed fine-mapping studies with large sample sizes are needed to confirm our findings. Thirdly, the clinical information on metastasis and survival of NSCLC could not be derived till now, which restricted further explores on the potential role of *CTLA-4*tagging polymorphisms in NSCLC progression and prognosis. Fourthly, the information about family cancer history was not collected. Finally, due to lack of the information about individual\'s lifestyle, further determination for the interactions of gene-gene and gene-environment were not carried out. In consideration of the complex pathological process of NSCLC, these gene and environmental risk factors should not be ignored.

In summary, the present case-control study highlights that *CTLA-4* rs733618 T\>C polymorphism was associated with the development of NSCLC in ≥ 60 years and even drinking subgroups. In addition, a larger population-based fine-mapping study as well as detailed functional assessment are necessary to confirm or refute our findings.

MATERIALS AND METHODS {#s4}
=====================

Study population and patient selection {#s4_1}
--------------------------------------

A total of 521 Eastern Chinese Han population with NSCLC were included in this study. These NSCLC patients were diagnosed from January 2014 to December 2016 at the Affiliated People\'s Hospital of Jiangsu University (Zhenjiang, China) and the Affiliated Union Hospital of Fujian Medical University (Fuzhou, China). Diagnosis of NSCLC was confirmed via histopathological examinations after operation or bronchoscope check. The selection criteria of NSCLC cases were: (1) sporadic NSCLC cases; (2) NSCLC patients without any treatment and (3) Eastern Chinese Han population. And the corresponding major exclusion criteria were: (1) autoimmune disease history; (2) NSCLC cases who received prior chemoradiotherapy and targeted threapy and (3) a history of another malignancy. Meanwhile, a total of 1,030 non-cancer controls were enrolled when they attended a routine physical examination in the Physical Examination Center of these hospitals. Additionally, the criteria for non-cancer controls selection was: (1) cancer-free subjects; (2) without autoimmune disease; (3) sex and gender matched to NSCLC patients; (4) unrelated subjects and (5) Eastern Chinese Han population. During recruitment, all study subjects signed the written informed consents following the Declaration of Helsinki. The information of risk factors and demographics was obtained by a pre-structured questionnaire. NSCLC cases and controls were well-matched in terms of age and sex (Table [1](#T1){ref-type="table"}). Subjects who smoked at least one cigarette per day over 1 year were considered as 'ever smokers' \[[@R21]\], and those who drinked no less than three times a week for more than 6 months were defined as 'ever drinkers' \[[@R21]\]. The Ethical Committee of Fujian Medical University approved the study protocols (No. 2017KY019).

Selection of CTLA-4 tagging SNPs {#s4_2}
--------------------------------

The *CTLA-4* tagging SNPs were selected through the Genome Variation Server (GVS) data (<http://gvs.gs.washington.edu/GVS147/>). The major included criterion were: (a) *P* value of HWE ≥ 0.05, (b) minor allele frequency (MAF) ≥ 0.05 (c) pairwise linkage disequilibrium (LD) *r*^2^ threshold of 0.8 between SNPs (*r*^2^ \> 0.8) and (d) the call rate ≥ 95 % in the CHB cohort were included \[[@R22]\]. Finally, *CTLA-4* rs3087243 G\>A, rs16840252 C\>T, rs733618 T\>C and rs231775 G\>A polymorphisms were eligible for study. Table [2](#T2){ref-type="table"} summarizes the information of the selected SNPs.

DNA extraction and genotyping {#s4_3}
-----------------------------

Two milliliters blood sample was donated by each enrolled subject and stored in Ethylenediamine tetraacetic acid (EDTA)-anticoagulation tube. DNA was elaborately extracted from lymphocytes by using the Promega kit (Promega, Madison, USA). We extracted DNA according to the manufacturer\'s instruction ( [www.promega.com/protocols/](http://www.promega.com/protocols/)). The genotypes of *CTLA-4* rs16840252 C\>T, rs231775 G\>A, rs3087243 G\>A and rs733618 T\>C polymorphisms were evaluated using a custom-by-design 48-Plex SNPscan Kit (Genesky Biotechnologies Inc., Shanghai, China) as presented in previous studies \[[@R23], [@R24]\]. Briefly, we first denatured 150ng DNA sample at 98°C for 5 min. The ligation reaction was performed in an ABI 2720 thermal cycler. A 48-plex fluorescence PCR reaction was carried out for each ligation product. Then, in an ABI 3730XL sequencer, the obtained PCR products were separated and detected by using capillary electrophoresis. The raw data were analyzed by GeneMapper 4.1 software (Applied Biosystems, USA). A 4% randomly selected DNA sample was reciprocally verified by another laboratory technician, and the reproducibility was 100%.

Statistical analysis {#s4_4}
--------------------

Statistical analysis of this case-control study was done using the SAS 9.4 Statistical Package for Windows (SAS Institute, Cary, NC). A *P* \< 0.05 (two--tailed) was accepted as the level of significance. The results of continuous variables were presented as mean ± standard deviation (SD). The mean values of age between NSCLC patients and non-cancer controls were calculated using the Student\'s *t*-test. The deviation of HWE in controls was analyzed using an online Pearson\'s two-sided χ^2^ test (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) \[[@R25]\]. The differences in smoking, drinking, demographic variables and the frequencies of genotypes between NSCLC cases and controls were also determined by χ^2^ test. The crude/adjusted ORs and the corresponding 95% CIs were harnessed to assess the relationship of *CTLA-4* rs16840252 C\>T, rs231775 G\>A, rs3087243 G\>A and rs733618 T\>C polymorphism genotypes with NSCLC risk. SHESIS online haplotype construction software \[(<http://analysis.bio-x.cn/myAnalysis.php>), Bio-X Inc., Shanghai, China\] was used to obtain the haplotypes \[[@R13]\]. The power value of this study was calculated by Power and Sample Size software (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>) \[[@R26]\].
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